Skip to main content
Terug
CAI logo

Caris Life Sciences, Inc.

Datakwaliteit: 100%
CAI
NASDAQ Healthcare Biotechnology
€ 19,26
▲ € 0,85 (4,62%)
Marktkapitalisatie: 5,44B
Dagbereik
€ 18,59 € 19,56
52-Weeksbereik
€ 17,15 € 42,50
Volume
2.807.289
50D / 200D Gem.
€ 21,91 / € 27,71
Vorige Slotkoers
€ 18,41

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E -10,1 0,4
P/B 9,4 2,9
ROE % 3,7
Net Margin % -66,3 3,9
Rev Growth 5Y % 10,0
D/E 0,7 0,2

Koersdoel Analisten

Hold
€ 31,33 +62.7%
Low: € 26,00 High: € 38,00
Forward K/W
109,4
Forward WPA
€ 0,18
WPA Groei (sch.)
+0,0%
Omzet Sch.
1 B

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 1,16
€ 1,14 – € 1,18
1,8 B 2
FY2029 € 1,07
€ 1,05 – € 1,09
1,7 B 4
FY2028 € 0,71
€ 0,44 – € 0,97
1,4 B 6

Belangrijkste Punten

Generating 66,90M in free cash flow
Capital efficient — spends only 2,00% of revenue on capex
ROIC of 3,54% — low return on invested capital
Interest coverage of 0,79× — tight debt servicing

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)96,97%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROIC3,54%
Net Margin-66,25%
Op. Margin5,56%

Veiligheid

Debt / Equity
0,66
Current Ratio7,85
Interest Coverage0,79

Waardering

P/E Ratio
-10,12
P/B Ratio9,43
EV/EBITDA111,36
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 96,97% Revenue Growth (3Y) 62,87%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 812,03M Net Income (TTM) -537,96M
ROE N/A ROA -47,79%
Gross Margin 66,40% Operating Margin 5,56%
Net Margin -66,25% Free Cash Flow (TTM) 66,90M
ROIC 3,54% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,66 Current Ratio 7,85
Interest Coverage 0,79 Dividend Yield 0,00%
Valuation
P/E Ratio -10,12 P/B Ratio 9,43
P/S Ratio 6,70 PEG Ratio 2,83
EV/EBITDA 111,36 Dividend Yield 0,00%
Market Cap 5,44B Enterprise Value 5,02B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2020
Revenue 812,03M 412,26M 306,13M 258,49M 294,01M
Net Income -537,96M -281,89M -341,42M -320,83M 27,73M
EPS (Diluted) -1,90 -2,70 -1,82 -1,57 1,55
Gross Profit 539,17M 178,78M 89,31M 80,02M 184,16M
Operating Income 45,11M -257,12M -319,55M -315,76M 139,09M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2020
Total Assets 1,13B 343,73M 412,90M 717,42M 2,61B
Total Liabilities 548,36M 2,84B 2,56B 2,42B 1,91B
Shareholders' Equity 577,31M -2,50B -2,14B -1,70B 702,24M
Total Debt 378,99M 424,26M 217,27M 270,87M 1,75B
Cash & Equivalents 797,80M 63,95M 56,40M 107,19M 53,55M
Current Assets 997,80M 215,73M 242,61M 516,04M 214,66M
Current Liabilities 127,15M 165,42M 95,14M 136,91M 320,25M